MTOR and cervical carcinoma: In cervical cancer, Xu et al. reported frequent alterations in the PI3K-AKT pathway, with PIK3CA being the most commonly mutated gene, occurring at an incidence of 31.7%.13 These findings suggest that the PI3K-AKT-mTOR pathway represents a classical therapeutic target, and mTOR inhibitors are currently being developed as potential therapeutic agents for various cancers.7,14